General Information of Drug (ID: DME3BJL)

Drug Name
PF-07062119
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DK87UQ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Guanylyl cyclase C (GUCY2C) TTLDPRG GUC2C_HUMAN Inhibitor [2]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Guanylyl cyclase C (GUCY2C) DTT GUCY2C 9.52E-03 2.35 5.13
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04171141) Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.. U.S. National Institutes of Health.
2 Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.